Last year, Cytek Biosciences Inc generated 116.73M USD for its biggest-performing segment, Biotechnology, pharmaceutical, distributor and CRO. The United States made the largest contribution, accounting for 95.25M USD last year. For the latest quarter, Cytek Biosciences Inc reported the revenue of 29.02M USD for the period ending 2026-06-30, which came from the top-performing segment, Biotechnology, pharmaceutical, distributor and CRO. United States contributed the highest revenue, at 28.22M USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Biotechnology, pharmaceutical, distributor and CRO

Academia and government

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

Biotechnology, pharmaceutical, distributor and CRO

116.73M(57.93%)

119.54M(59.64%)

110.87M(57.44%)

90.33M(55.07%)

68.53M(53.56%)

47.16M(50.80%)

26.31M(45.45%)

Academia and government

84.76M(42.07%)

80.91M(40.36%)

82.14M(42.56%)

73.71M(44.93%)

59.41M(46.44%)

45.67M(49.20%)

31.58M(54.55%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

United States

EMEA

APAC

Other

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

United States

95.25M(47.27%)

92.61M(46.20%)

102.08M(52.89%)

94.59M(57.67%)

72.72M(56.84%)

55.48M(59.76%)

38.15M(65.90%)

EMEA

55.88M(27.73%)

62.34M(31.10%)

53.18M(27.55%)

43.96M(26.80%)

36.97M(28.89%)

25.91M(27.91%)

11.48M(19.83%)

APAC

41.08M(20.39%)

35.77M(17.84%)

31.60M(16.37%)

22.52M(13.73%)

16.08M(12.57%)

10.74M(11.57%)

8.07M(13.94%)

Other

9.28M(4.61%)

9.73M(4.86%)

6.15M(3.19%)

2.96M(1.81%)

2.18M(1.70%)

710.00K(0.76%)

189.00K(0.33%)